Newsroom press releases

06/05/25 - 17:41

Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidance (268.56 KB)

Financial Data

28/04/25 - 16:50

Shareholders' Meeting 2025 (138.81 KB)

Other

18/04/25 - 18:11

Diasorin receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX® (161.29 KB)

Products

07/04/25 - 13:07

Publication of the lists of candidates for the appointment of the Board Directors, the Board of Statutory Auditors and relevant proposals for resolution. (111.09 KB)

Financial Disclosures

04/04/25 - 0:59

Notice pursuant to art. 144-octied, para. 2 of CONSOB regulation No. 1971/1999 (125.78 KB)

Other

31/03/25 - 19:36

Adoption of the enhancement of the increased voting rights mechanism: withdrawal exercised by 1.69% of the share capital. Statutory option and pre-emption offer period to start on 31 March 2025. (119.78 KB)

Other

18/03/25 - 11:54

Diasorin launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark (126.65 KB)

Products Molecular

14/03/25 - 16:29

The Board of Directors of Diasorin SpA approves FY2024 Results with revenues and net profit in expansion compared to Previous Year; Proposed Ordinary Dividend of € 1.20 per share (239.79 KB)

Financial Data

03/03/25 - 21:19

Registration and publication the minutes of shareholders' meeting. Withdrawal right. (101.04 KB)

Other

03/03/25 - 21:05

Notice to Shareholders - Information regarding the exercise of the withdrawal right (88.54 KB)

Other

28/02/25 - 11:49

The Extraordinary Meeting of Shareholders approves the enhancement of the increased voting rights mechanism (111.6 KB)

Other

27/01/25 - 20:14

Proposal to enhance the increased voting rights mechanism to support the Company's growth strategy, also by external lines, and reward a shareholder base with a long-term investment horizon (126.5 KB)

Other

24/12/09 - 1:00

Financial instruments to employees (26.76 KB)

Financial Data

30/10/09 - 1:00

The BoD approves Q3'09 results (212.92 KB)

Financial Data

12/10/09 - 2:00

Strengthening of group's R&D team (99.72 KB)

Other

08/10/09 - 2:00

2009 Financial calendar update (97.3 KB)

Financial Data

05/10/09 - 2:00

Financial instruments to employees (27.08 KB)

Financial Data

06/08/09 - 2:00

The BoD approves H1'09 results (214.79 KB)

Financial Data

08/06/09 - 2:00

2009 Financial calendar update (97.33 KB)

Financial Data

18/05/09 - 2:00

Financial instruments to employees (26.65 KB)

Financial Data

10/04/09 - 2:00

Corporate Governance Report at December 2008. (97.57 KB)

Financial Data

08/04/09 - 2:00

2009 Financial calendar update (103.88 KB)

Financial Data

19/03/09 - 1:00

The BoD approves FY 2008 results (221.59 KB)

Financial Data

20/02/09 - 1:00

Financial instruments to employees (26.39 KB)

Financial Data

13/02/09 - 1:00

The BoD approves Q4'08 results (170.79 KB)

Financial Data

28/01/09 - 1:00

2009 Financial calendar (93.96 KB)

Financial Data

08/01/09 - 1:00

FDA clearance to five LIAISON products (96.84 KB)

Products Immunodiagnostic